GSK2857916 (DREAMM5) (GlaxoSmithKline Research)
Description: As Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5
Mechanism of action: anti BCMA antibody drug conjugate
Target Patient Population: Multiple Myeloma
Study Design: Study Drug is administered IV every 3 weeks. Combination arms with Belantamab + other anti-myeloma agents